HighCape Capital Acquisition II filed with the SEC to offer 20 million units at $10 per unit, each consisting of one share of Class A common stock and one-fourth of one redeemable warrant. Whole warrants would be exercisable at $11.50 for one share.
HighCape in the filing said it will concentrate on companies engaged in life sciences and life sciences related industries.
The SPAC is led by CEO and Director Kevin Rakin, co-founder and partner of HighCape. He has more than 30 years of experience as an executive and investor in the life sciences industry, according to the filing.
The SPAC expects to list on the Nasdaq under HCCRU. Read more.
